Elan will spend $1 billion of the $3.25 billion one-off payment it is receiving from Biogen Idec for the return of rights to the blockbuster multiple sclerosis drug Tysabri to buy back around a 16% stake in the Irish company.
Elan today released limited additional information on how it intends to use the proceeds of the transaction, which it announced...
Welcome to Scrip
Create an account to read this article
Already a subscriber?